Drug intelligence / Profile preview

Advagene RSV immunotherapy

Development stage: Preclinical
Lead developer: Advagene
Modality: Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics

Overview

Advagene RSV immunotherapy is an adjuvanted protein-based vaccine or immunotherapy candidate developed by Advagene for the prevention or treatment of Respiratory Syncytial Virus (RSV) infection. The product utilizes Advagene's proprietary LTh(αK) technology platform, which consists of a detoxified heat-labile enterotoxin (LT) from *Escherichia coli*. This immunomodulatory protein serves as a potent mucosal adjuvant, designed to enhance both local mucosal and systemic immune responses against RSV antigens. Currently in the exploration or preclinical stage, the therapy is intended for intranasal administration to stimulate robust T-cell and B-cell responses at the site of viral entry, potentially offering a protective or therapeutic effect against RSV-induced respiratory disease.

Other names: RSV infection immunotherapy呼吸道融合病毒感染免疫治療Advagene RSV vaccineAdvagene-Respiratory syncytial virus (RSV) antigens (not specified)-LTh(αK) immunomodulatory protein (adjuvant)-protein immunotherapy-adjuvanted vaccine/therapy-Respiratory syncytial virus (RSV) infection

Targets

FIP-Lti (Lentinus tigrinus immunomodulatory protein)RSV G (Respiratory syncytial virus attachment glycoprotein)

Beyond the preview

Go deeper on Advagene RSV immunotherapy.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Advagene RSV immunotherapy.

Explore the full profile